Literature DB >> 16868573

A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.

M Gusella1, C Bolzonella, G Crepaldi, E Ferrazzi, R Padrini.   

Abstract

Thymidylate synthase (TYMS) is the main molecular target for fluoropyrimidine anticancer drugs, and its expression has been correlated with the number of repeats of a 28-bp sequence in the 5'-untranslated region of the TYMS gene and with the presence of a G --> C single-nucleotide polymorphism in the second repeat of 3R alleles. Based on this double polymorphism, three main TYMS alleles have so far been identified: TYMS 2R, TYMS 3RC and TYMS 3RG. During genetic analysis of TYMS polymorphisms in 100 colorectal cancer patients, three patients revealed an unexpected 113-bp band after electrophoresis of the restriction fragment length polymorphism analysis. Subsequent sequencing revealed two 28-bp repeats in the 5'-untranslated region and the presence in both repeats of cytosine instead of guanine at the 12th nucleotide. This allele variant (TYMS 2RC) has not been previously described in man. All three patients were heterozygotes for TYMS 2RC and experienced grade 2-3 chemotherapy-related toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868573     DOI: 10.1038/sj.tpj.6500401

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  7 in total

Review 1.  The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.

Authors:  Caitriona Ryan; Alan Menter; Richard B Warren
Journal:  Mol Diagn Ther       Date:  2010-04-01       Impact factor: 4.074

2.  Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers.

Authors:  Bart A W Jacobs; Maarten J Deenen; Dick Pluim; J G Coen van Hasselt; Martin D Krähenbühl; Robin M J M van Geel; Niels de Vries; Hilde Rosing; Didier Meulendijks; Artur M Burylo; Annemieke Cats; Jos H Beijnen; Alwin D R Huitema; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

3.  Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.

Authors:  Fabienne Thomas; Janelle M Hoskins; Anne Dvorak; Benjamin R Tan; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2010-12       Impact factor: 2.533

4.  Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.

Authors:  David Páez; Laia Paré; Albert Altés; Francesc Josep Sancho-Poch; Lourdes Petriz; Jordi Garriga; Josep Maria Monill; Juliana Salazar; Elisabeth del Rio; Agustí Barnadas; Eugenio Marcuello; Montserrat Baiget
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-18       Impact factor: 4.553

5.  Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients.

Authors:  Karolina Tecza; Jolanta Pamula-Pilat; Joanna Lanuszewska; Dorota Butkiewicz; Ewa Grzybowska
Journal:  Oncotarget       Date:  2018-01-10

6.  Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.

Authors:  M Gusella; A C Frigo; C Bolzonella; R Marinelli; C Barile; A Bononi; G Crepaldi; D Menon; L Stievano; S Toso; F Pasini; E Ferrazzi; R Padrini
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

7.  Thymidylate synthase polymorphisms, folate and B-vitamin intake, and risk of colorectal adenoma.

Authors:  R A Hubner; J-F Liu; G S Sellick; R F A Logan; R S Houlston; K R Muir
Journal:  Br J Cancer       Date:  2007-10-30       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.